Specialized in early-stage and growth-stage investment of Biotech and Healthcare industry, specially in IVD, precision medicine and innovative therapy. Board Member of Chromai, OriginGene-Tech, Casia-Health, Essentia Biosciences in Beijing, and Board Observer of Haosi Biotech and SinoGene in Beijing. YuanBio Venture Capital focuses on early and growth stage life science and healthcare investment. Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally… Show more Specialized in early-stage and growth-stage investment of Biotech and Healthcare industry, specially in IVD, precision medicine and innovative therapy. Board Member of Chromai, OriginGene-Tech, Casia-Health, Essentia Biosciences in Beijing, and Board Observer of Haosi Biotech and SinoGene in Beijing. YuanBio Venture Capital focuses on early and growth stage life science and healthcare investment. Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally. Total AUM is close to 5 billion RMB. Portfolio includes over 70 companies across new drug, medtech, diagnosis and health services sectors. YuanBio Venture Capital has outstanding return for its investors and is recognized as China Top 10 Healthcare VCs, Most Active Healthcare Investment Firms several times. YuanBio Venture Capital aims to be one of the most successful healthcare venture capital firm in China. Show less

Specialized in early-stage and growth-stage investment of Biotech and Healthcare industry, specially in IVD, precision medicine and innovative therapy. Board Member of Chromai, OriginGene-Tech, Casia-Health, Essentia Biosciences in Beijing, and Board Observer of Haosi Biotech and SinoGene in Beijing.YuanBio Venture Capital focuses on early and growth stage life science and healthcare investment. Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally… Show more Specialized in early-stage and growth-stage investment of Biotech and Healthcare industry, specially in IVD, precision medicine and innovative therapy. Board Member of Chromai, OriginGene-Tech, Casia-Health, Essentia Biosciences in Beijing, and Board Observer of Haosi Biotech and SinoGene in Beijing.YuanBio Venture Capital focuses on early and growth stage life science and healthcare investment. Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally. Total AUM is close to 5 billion RMB. Portfolio includes over 70 companies across new drug, medtech, diagnosis and health services sectors. YuanBio Venture Capital has outstanding return for its investors and is recognized as China Top 10 Healthcare VCs, Most Active Healthcare Investment Firms several times. YuanBio Venture Capital aims to be one of the most successful healthcare venture capital firm in China. Show less

Focus on gene-related tech and service, while interested in sectors as biotech, medical, and healthcare as well as other hi-tech and consumer industry. Investigated 900+ startups, and have invested 3 companies, Reforgene in Guangzhou, QihanBio in Hangzhou, and IntuitionBio in Hangzhou. Legend Star, founded in 2008, currently manages five angel investment funds with a total amount of more than RMB 2 billion, and has invested in nearly 300 projects. As one of Legend Holdings’ early… Show more Focus on gene-related tech and service, while interested in sectors as biotech, medical, and healthcare as well as other hi-tech and consumer industry. Investigated 900+ startups, and have invested 3 companies, Reforgene in Guangzhou, QihanBio in Hangzhou, and IntuitionBio in Hangzhou. Legend Star, founded in 2008, currently manages five angel investment funds with a total amount of more than RMB 2 billion, and has invested in nearly 300 projects. As one of Legend Holdings’ early investments and incubations, Legend Star is dedicated to ventures for over three decades and has accumulated rich resources, with which it provides entrepreneurs with a featured service package of “angel investment and in-depth incubation.” Show less

Cofounded Watson Capital in 2016, and have raised 136 million RMB for the first fund, and has invested 8 companies since the first investment in Mar 2017. As professional investor
in Biotech, Medical and Healthcare (BMH) sectors, WSCAP, short for Watson Capital, or “宁波梅山保税港区沃生投资管理有限公司” in Chinese, was founded in 2016, by four experienced experts in BMH sectors in China. As venture capital company in biotech, medical and healthcare sectors, WSCAP independently manage fund, raise money… Show more Cofounded Watson Capital in 2016, and have raised 136 million RMB for the first fund, and has invested 8 companies since the first investment in Mar 2017. As professional investor
in Biotech, Medical and Healthcare (BMH) sectors, WSCAP, short for Watson Capital, or “宁波梅山保税港区沃生投资管理有限公司” in Chinese, was founded in 2016, by four experienced experts in BMH sectors in China. As venture capital company in biotech, medical and healthcare sectors, WSCAP independently manage fund, raise money from Chinese companies and investors, while invest Chinese startups in biotech, medical and healthcare sectors, such as medical device producers, medicine manufactures, or new diagnostic and therapeutic technology developers, etc. Taking charge of the first fund, 140 million RMB, which was invested by several big Pharma companies and specialists in China, WSCAP are dedicated to be the preferred partner for entrepreneurs, investors and industry to build great companies in China that discover and develop products that make a difference in biotech, medical and healthcare industry. Show less

Investigated 500+ startups in gene-related industry, and was responsible for portfolio management. Legend Star, founded in 2008, currently manages five angel investment funds with a total amount of more than RMB 2 billion, and has invested in nearly 300 projects. As one of Legend Holdings’ early investments and incubations, Legend Star is dedicated to ventures for over three decades and has accumulated rich resources, with which it provides entrepreneurs with a featured service package… Show more Investigated 500+ startups in gene-related industry, and was responsible for portfolio management. Legend Star, founded in 2008, currently manages five angel investment funds with a total amount of more than RMB 2 billion, and has invested in nearly 300 projects. As one of Legend Holdings’ early investments and incubations, Legend Star is dedicated to ventures for over three decades and has accumulated rich resources, with which it provides entrepreneurs with a featured service package of “angel investment and in-depth incubation.” Show less

In charge of investment of healthcare industry in CAC capital, and responsible for team building, strategy planning and overall executive procedure of industry investigation, deal sourcing, due diligent, and portfolio management. Assisted fund raising and branding. Investigated 150+ startups, and have invested 1 company, and raised 5 million CNY for the Beijing fund in 2014. Investigated 300+ startups and have invested 3 companies in 2015.

In charge of investment of healthcare industry in CAC capital, and responsible for team building, strategy planning and overall executive procedure of industry investigation, deal sourcing, due diligent, and portfolio management. Assisted fund raising and branding.Investigated 150+ startups, and have invested 1 company, and raised 5 million CNY for the Beijing fund in 2014. Investigated 300+ startups and have invested 3 companies in 2015.

Found LittleMore, a startup on foods and drinks, from Sep 2013 to Feb 2014. Provided dim sum, fruits, and other refreshments to customers in Nanshan District, such as Tencent, Lenovo, BAK, FIYTA, Kingdee, etc. Built standardized production streamline (offline) and online platform of marketing and Sales.

Product manager in 360 Gene, a DTC genetic testing startup, from June to August in 2013. Responsible for product development and supply chain management. Assisted building e-commercial platform and database, as well as marketing and sales.

In charge of team building, strategy planning, and eHealth platform building. Have developed B2C platform of healthcare service associated with offline team in BGI Health. Operated eHealth Platform, and provided HPV gene test to individual customers, and got 300+ HPV test kits be sold.

Investigated US healthcare market, esp. on prenatal testing patent (NIFTY etc.). Coordinating between CHOP lab in US and HQs in Shenzhen, assisting in clinic lab building in CHOP. Seeking representative in South Americas. Earned the 1st individual genome analysis contract for BGI in North Americas.

Business development in Massachusetts as sales, and maintained key contacts, such as Boston University, BWH, Children’s Hospital Boston, Dana Farber, Harvard, MGH, Manus Bio, McGill, Pfizer, Tufts University, UCONN, and UMASS, etc. Earned 75 opportunities, got 13 contracts, 1M USD contract, and 0.73M USD revenue. Investigated US healthcare market, especially on prenatal testing patent (NIFTY, etc.). Earned the first individual genome analysis contract for BGI in North Americas.

Coordinated between local sales in US and tech support team in Shenzhen and was responsible for projects management. Maintained key accounts such as BWH, Children's Hospital Boston, Dana Farber, Harvard, MGH, McGill, Otogenetics, Pfizer, and UMASS etc. Collaborated with Merck, Pfizer, and McGill, etc.

Reviewed studies about petroleum-related microbe to explorer petroleum microbes, built sales tools for collaborators and developed engineering strains.